BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30333474)

  • 1. The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer.
    Atiq SO; Atiq OO; Atiq MO; Phillips KC; Jacks BB; Moreno M; Maraboyina S; Atiq OT
    Am J Case Rep; 2018 Oct; 19():1241-1244. PubMed ID: 30333474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
    Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
    Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
    Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
    Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
    Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
    Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
    Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A
    Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
    Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
    Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
    Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
    Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study.
    Fountzilas G; Kosmidis P; Sridhar KS; Kalogera-Fountzila A; Banis K; Dimitriadis A; Avramidis V; Nikolaou A; Zaramboukas T; Skarlos D; Vritsios A; Daniilidis I
    Cancer Invest; 1996; 14(3):189-96. PubMed ID: 8630678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. A pilot study.
    Abitbol AA; Schwade JG; Lewin AA; Sridhar K; Brandon AH; Markoe AM; Casiano RR; Houdek PV; Serago C; Miller DJ
    Am J Clin Oncol; 1992 Jun; 15(3):250-5. PubMed ID: 1590280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two cases of combination therapy with cetuximab, paclitaxel, and cisplatin for advanced head and neck cancer.
    Hoch MA; Cousins K; Nartey R; Riley K; Hartranft M
    J Oncol Pharm Pract; 2018 Oct; 24(7):553-554. PubMed ID: 28764598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Schultz JD; Bran G; Anders C; Sadick H; Faber A; Hörmann K; Sauter A
    Oncol Rep; 2010 Nov; 24(5):1213-6. PubMed ID: 20878112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
    Monnier L; Touboul E; Durdux C; Lang P; St Guily JL; Huguet F
    Head Neck; 2013 Dec; 35(12):1683-8. PubMed ID: 23359352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; McClurkan S; Gray JR; Stroup SL; Burris HA; Yardley DA; Bradof JE; Yost K; Ellis JK; Greco FA
    Cancer J; 2002; 8(4):311-21. PubMed ID: 12184409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
    Sheth S; Weiss J
    Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
    Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
    Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS
    Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.